NuVasive will pay approximately $4.5 million for the company, which NuVasive has been involved with since 2010 as a manufacturing partner. Company executives said the deal will reduce the time for NuVasive device development; all 65 ANC employees will be retained.
More Articles on Devices:
DePuy Receives FDA Supplemental Pre-Market Approval for Hip Devices
Smith & Nephew Revenue Down 4 percent in Q1, $300M Share Buyback Announced
Study: Limiting Device Company, Provider Relationships Could Hurt Innovation
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
